Featured Research

from universities, journals, and other organizations

Prostate cancer risk reduction in men taking dutasteride, but some concerns remain

Date:
January 22, 2013
Source:
Elsevier
Summary:
The four-year REDUCE (REduction by DUtasteride of prostate Cancer Events) clinical study evaluated prostate cancer risk reduction in men taking dutasteride, a 5-alpha-reductase inhibitor (5ARI) typically used to treat enlarged prostate. REDUCE results showed that dutasteride decreased the risk of biopsy detectable prostate cancer by 22.8 percent compared to a placebo group, but concerns remained about the drug's effectiveness.

The four-year REDUCE (REduction by DUtasteride of prostate Cancer Events) clinical study evaluated prostate cancer risk reduction in men taking dutasteride, a 5-alpha-reductase inhibitor (5ARI) typically used to treat enlarged prostate. REDUCE results showed that dutasteride decreased the risk of biopsy detectable prostate cancer by 22.8 percent compared to a placebo group, but concerns remained about the drug's effectiveness.

Results from a follow-up study are now published in The Journal of Urology.

"The REDUCE Follow-up Study was a two-year observational follow-up of men who participated in the four-year REDUCE trial," says lead investigator Robert L. Grubb III, Associate Professor of Surgery (Urology), Washington University of Medicine in St. Louis, Missouri. "The primary objective was to collect data on the occurrence of new cases of prostate cancer for two years beyond REDUCE."

Nearly 2,800 men from the REDUCE study participated, representing extension safety and at-risk populations. In the original study, about half were treated with dutasteride and the remainder received a placebo.

Shortly after the REDUCE study's conclusion, Dr. Grubb and co-investigators followed participants with a clinic visit. They also conducted up to two annual telephone calls, collecting patient data on prostate cancer events, chronic medication use, prostate specific antigen levels, and serious adverse events. No drugs were administered and no additional biopsies were performed except those "for-cause" when clinically indicated.

Results showed that few new prostate cancers were detected during the two-year follow-up in either treatment group and no deaths were reported. However, the former dutasteride group produced double the number of cancers than the former placebo group (14 vs. 7). Investigators hypothesize that any prostate cancer that may have been suppressed by dutasteride during REDUCE was no longer being suppressed for those subjects who did not continue on 5ARI therapy. To some extent, observations during the follow-up study support this concept.

Using Gleason scores, the system used to evaluate the prognosis of prostate cancer, no high grade prostate cancers (Gleason Score 8-10) were detected. No new safety issues surfaced.

More men from the placebo group underwent biopsy (11.6 percent) than men from the dutasteride group (7.9 percent). A higher incidence of prostate cancer (1.3 percent) was observed in men in the dutasteride group who did not continue 5ARI treatment. Overall, men in either group who took a 5ARI during the follow-up study tended to have fewer cancers.

"Although this study provides real-world observational data for subjects who had been randomized to four years of dutasteride therapy, it has limitations," cautions Dr. Grubb. "Men in the at-risk population had a low risk of prostate cancer diagnosis due to several prior negative biopsies and corresponding conclusions are specific to the population studied. In addition, some men who dropped out of REDUCE early may have been off dutasteride treatment for longer than the two-year observational period."

The two years of additional study have been useful in demonstrating a low rate of new prostate cancer diagnoses among men from the REDUCE study.


Story Source:

The above story is based on materials provided by Elsevier. Note: Materials may be edited for content and length.


Journal Reference:

  1. Robert L. Grubb, Gerald L. Andriole, Matthew C. Somerville, Chrysa Mahoney, Michael J. Manyak, Ramiro Castro. The REDUCE Follow-Up Study: Low Rate of New Prostate Cancer Diagnoses Observed During a 2-Year, Observational, Followup Study of Men Who Participated in the REDUCE Trial. The Journal of Urology, 2012; DOI: 10.1016/j.juro.2012.09.099

Cite This Page:

Elsevier. "Prostate cancer risk reduction in men taking dutasteride, but some concerns remain." ScienceDaily. ScienceDaily, 22 January 2013. <www.sciencedaily.com/releases/2013/01/130122101634.htm>.
Elsevier. (2013, January 22). Prostate cancer risk reduction in men taking dutasteride, but some concerns remain. ScienceDaily. Retrieved July 31, 2014 from www.sciencedaily.com/releases/2013/01/130122101634.htm
Elsevier. "Prostate cancer risk reduction in men taking dutasteride, but some concerns remain." ScienceDaily. www.sciencedaily.com/releases/2013/01/130122101634.htm (accessed July 31, 2014).

Share This




More Health & Medicine News

Thursday, July 31, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Health Insurers' Profits Slide

Health Insurers' Profits Slide

Reuters - Business Video Online (July 30, 2014) — Obamacare-related costs were said to be behind the profit plunge at Wellpoint and Humana, but Wellpoint sees the new exchanges boosting its earnings for the full year. Fred Katayama reports. Video provided by Reuters
Powered by NewsLook.com
Concern Grows Over Worsening Ebola Crisis

Concern Grows Over Worsening Ebola Crisis

AFP (July 30, 2014) — Pan-African airline ASKY has suspended all flights to and from the capitals of Liberia and Sierra Leone amid the worsening Ebola health crisis, which has so far caused 672 deaths in Guinea, Liberia and Sierra Leone. Duration: 00:43 Video provided by AFP
Powered by NewsLook.com
At Least 20 Chikungunya Cases in New Jersey

At Least 20 Chikungunya Cases in New Jersey

AP (July 30, 2014) — At least 20 New Jersey residents have tested positive for chikungunya, a mosquito-borne virus that has spread through the Caribbean. (July 30) Video provided by AP
Powered by NewsLook.com
Xtreme Eating: Your Daily Caloric Intake All On One Plate

Xtreme Eating: Your Daily Caloric Intake All On One Plate

Newsy (July 30, 2014) — The Center for Science in the Public Interest released its 2014 list of single meals with whopping calorie counts. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

    Environment News

    Technology News



      Save/Print:
      Share:  

      Free Subscriptions


      Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

      Get Social & Mobile


      Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

      Have Feedback?


      Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
      Mobile iPhone Android Web
      Follow Facebook Twitter Google+
      Subscribe RSS Feeds Email Newsletters
      Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins